Cancer screening decisions
Tumour markers for screening:why context matters more than the panel.
Tumour markers can be useful in specific cancer pathways, but they are not a general blood test that can rule cancer in or out. Their meaning depends on the clinical question, symptoms and risk.
Tumour markers are not general-purpose cancer screening tests.
Tumour markers are substances that can sometimes be raised in cancer, but they can also be raised for non-cancer reasons, and some cancers do not produce a useful marker at all. That is why a normal marker does not rule out cancer and a raised marker does not prove cancer. [1]
Most tumour markers are used in a specific diagnostic or monitoring context rather than as a blanket blood panel for people without symptoms. The clinical question and the follow-up pathway matter as much as the number itself.
The same tumour marker can mean different things depending on symptoms, risk, imaging and the reason it was ordered.
A raised value may need imaging, examination or another test before a diagnosis can be made.
Using several markers together does not turn them into a reliable all-cancer screen.
What are tumour markers actually used for?
Cancer Research UK explains that tumour markers may be used together with other tests to help diagnose some cancers, guide treatment, monitor response or look for recurrence. [1]
Those are different uses. A marker that is helpful after a diagnosis may perform poorly as a screening test in a healthy population. The chance that an abnormal result represents cancer depends heavily on why the test was ordered and the person's underlying risk.
Tumour markers therefore need clinical context. They should not be treated like a general wellness score.
Why can tumour-marker screening mislead?
| Problem | Why it happens | What it can lead to |
|---|---|---|
| Marker raised without cancer | Some markers rise with benign disease, inflammation, age or other conditions. | Anxiety, repeat testing, imaging or invasive investigation. |
| Cancer present with normal marker | Not every cancer produces a measurable marker and some markers rise only in certain stages or subtypes. | False reassurance if a normal result is treated as an all-clear. |
| Small chance of disease | In low-risk populations, even a reasonably accurate test can generate many false positives. | More people may undergo follow-up than the number who benefit from early detection. |
| Unclear threshold | A borderline result may not have one obvious meaning. | Repeat testing or specialist interpretation may be needed. |
Are PSA and CA125 exceptions?
They are examples of markers used in defined pathways, but they are not universal cancer screens.
For prostate cancer, the UK NSC's 2026 recommendation supports targeted PSA screening only for a specific higher-risk group with a pathogenic BRCA2 variant and relevant family history. It continues to recommend against population-wide prostate screening. [2]
For ovarian cancer, NICE uses CA125 in people with persistent symptoms within a diagnostic pathway and interprets the result with age and ultrasound. NICE also warns against using CA125 in isolation in some younger patients. [3]
Why is an “all-cancer tumour marker panel” a weak screening idea?
Using several markers can look more comprehensive. But each marker can still produce false positives, false negatives or results that are hard to interpret.
NICE guidance for metastatic cancer of unknown primary is a useful illustration of how selective tumour-marker testing is in specialist care. It advises against measuring tumour markers routinely during diagnosis except in particular clinical presentations, such as PSA when prostate cancer is compatible with the presentation or CA125 in relevant ovarian-cancer presentations. [4]
If testing is selective even in complex cancer diagnosis, a broad marker panel in an asymptomatic person should not be treated as a simple all-clear test.
What if you have symptoms or a strong family history?
Symptoms need diagnostic assessment rather than a generic screening panel. The right pathway may include examination, imaging, standard blood tests, a marker test or specialist referral depending on the symptom.
Family history can change cancer risk. The right response may be a recognised screening programme, genetic assessment or condition-specific follow-up. Buying several tumour markers is not a substitute for that pathway.
Tell the clinician about the exact family history and age at diagnosis rather than assuming one marker covers inherited risk.
Questions to ask before paying for a tumour-marker test
- Is this test being used for screening, diagnosis or monitoring?
- What cancer or clinical question is it meant to address?
- How often is the marker raised for non-cancer reasons?
- Can the cancer be present with a normal result?
- What happens after a raised result?
- Would another evidence-based screening or diagnostic pathway be more appropriate?
- Who interprets the result and arranges follow-up?
These questions help separate a clinically justified marker test from a broad test sold mainly because the word “cancer” is worrying.
How does this fit with private health screening?
Private screening can be useful when it is targeted to risk and linked to a defined follow-up pathway. It should not promise that normal tumour markers rule out cancer.
The separate screening-benefits guide explains false positives, false negatives and overdiagnosis. The planned private-health-screening service page will own the practice's actual screening offer once that service page is built and verified.
If someone offers a broad tumour-marker panel, ask these questions
First ask what cancer the marker is meant to screen for. A marker that can help monitor a known cancer may not work well as a screening test in a person with no symptoms. The use has to match the evidence.
Ask what else can raise the marker. Some tumour markers can be abnormal for reasons other than cancer. That means a positive result may lead to scans or other tests even when cancer is not present.
Ask what a normal result means. A normal tumour marker does not rule out every cancer. A panel can therefore give false reassurance as well as false alarms.
Ask what happens after an abnormal result. Will the test be repeated? Will you need imaging, a specialist appointment or another procedure? Who will interpret the result in the context of your age, symptoms and risk?
Ask why this marker is better than an established screening programme or symptom-led pathway for you. For example, PSA is used in a defined prostate assessment context, while CA125 is used in specific ovarian-cancer pathways. Those uses do not make a general multi-marker cancer screen valid.
Do not use a private marker panel to delay medical review of a symptom such as unexplained bleeding, a new lump, persistent pain, unexplained weight loss or another change that needs assessment. Symptoms need the right clinical pathway, not a screening package.
Why context matters more than the name of the marker
A tumour marker is a lab result, not a cancer diagnosis. The same marker can rise for more than one reason. Some cancers do not raise the marker at all.
This is why doctors use a marker in a defined pathway. The result may be one part of a wider check that includes symptoms, examination, scans or another test.
A test used to follow a known cancer can be useful because the diagnosis is already known. That does not mean the same test works well for screening people who feel well.
Ask what the marker is meant to do in your case. If the answer is only “to check for cancer”, ask which cancer, what evidence supports that use and what happens after either result.
A good screening test needs more than the ability to measure a substance in blood. It needs evidence that using it in the intended group creates more benefit than harm.
What patients say about the consultation experience.
Patient reviews can help you understand how a consultation feels. They do not prove that a diagnosis will be found or that a treatment will work.
Individual reviews reflect personal experiences and do not predict diagnosis, treatment response or outcome.
“patient, understanding and kind”
Google reviewer
“warm and compassionate bedside manner”
Google reviewer
“takes incredible care to get to know her patients”
Google reviewer
Common questions
Can tumour-marker blood tests screen for all cancers?
No. Tumour markers are not universal cancer-screening tests. Some cancers do not produce a useful marker, and markers can rise for non-cancer reasons. A normal result cannot rule out all cancer, and a raised result usually needs clinical interpretation and further assessment.
What are tumour markers used for?
Depending on the marker and cancer type, they may support diagnosis, help plan treatment, monitor response or check for recurrence. Their usefulness depends on the clinical context. A marker that helps after a cancer diagnosis may not be suitable for screening healthy people. [1]
Does a normal CA125 or PSA mean I do not have cancer?
Why can tumour markers be raised without cancer?
Some markers can rise because of benign conditions, inflammation or other biological factors. That reduces their specificity as general screening tests. A raised value may therefore lead to repeat testing, imaging or specialist review before anyone can say what it means.
Is a panel of several tumour markers more reliable?
Not necessarily. Each marker still has its own limitations. Adding more markers can increase the number of abnormal or unclear results without creating a valid all-cancer screen. The best test is the one supported for the specific clinical question and risk profile.
What should I do if I have cancer symptoms?
Do not rely on a screening marker panel. Symptoms need medical assessment and may require examination, imaging, standard tests or referral. Tell the clinician the symptoms and family history so the correct diagnostic pathway can be chosen.
Medical sources and further reading
- Cancer Research UK: Blood tests and tumour markers. Explains common uses and limitations of tumour-marker tests.
- UK NSC: Prostate cancer screening recommendation. Records the 2026 targeted PSA-screening recommendation and the continued position against population-wide screening.
- NICE NG12: Suspected cancer, recognition and referral. Shows condition- and symptom-specific use of markers such as CA125 and PSA.
- NICE CG104: Metastatic malignant disease of unknown primary origin. Shows selective tumour-marker use even within specialist diagnostic pathways.
A marker is part of a pathway, not an all-clear certificate.
Use tumour markers for the job they are validated for, with a plan for what follows the result.